A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants

Merck Sharp & Dohme LLC

Summary

The purpose of this trial is to compare what happens to MK-1406 in the body of healthy participants when it is given as 2-injections and 3-injections. Researchers also want to learn about the safety of MK-1406 and if people tolerate it.

Eligibility

Age range: 18–64 years
Sex: All
Healthy volunteers: Yes

Detailed criteria

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Is in good health * Has body mass index (BMI) 18.0 to 32.0 kg/m\^2 Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * History of clinically significant endocrine, Gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases * History of cancer (malignancy)

Interventions

Drug
MK-1406
Subcutaneous administration

Locations (3)

Research Centers of America ( Hollywood ) ( Site 0008)
Hollywood, Florida
954-990-7649
Hassman Research Institute Marlton Site ( Site 0001)
Marlton, New Jersey
856-452-9901
Velocity Clinical Research, Cleveland ( Site 0005)
Cleveland, Ohio
216-682-0320

A Randomized, Open Label, Parallel Group Phase 1 Study to Compare Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MK-1406 as Three Injections Compared With Two Injections in Healthy Adult Participants

Summary

Eligibility

Interventions

Locations (3)

Run this study?

Details

Conditions